Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
13 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
13 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
12 May 2025 Date | | - Cons. EPS | - EPS |
27 Mar 2025 Date | | - Cons. EPS | - EPS |
14 Nov 2024 Date | | - Cons. EPS | - EPS |
13 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
13 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
12 May 2025 Date | | - Cons. EPS | - EPS |
27 Mar 2025 Date | | - Cons. EPS | - EPS |
14 Nov 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Zhengbin Yao CEO | NASDAQ (NMS) Exchange | 04272N102 Cusip |
US Country | 52 Employees | - Last Dividend | - Last Split | - IPO Date |
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical entity focused on addressing the critical unmet medical needs of cancer patients primarily in the United States. Founded in 2021 and situated in Newtown Square, Pennsylvania, the company is dedicated to the pursuit of novel medical solutions through the identification, development, and commercialization of therapeutic interventions for cancer. With a clear emphasis on bringing targeted cancer therapies to the market, especially for non-small cell lung cancer (NSCLC) and other solid tumors, ArriVent BioPharma underscores its role in the oncological landscape by tackling complex challenges in the current treatment paradigms. The company's robust development strategies and strategic alliances underscore its potential to make significant advancements in oncology therapeutics.
A third-generation tyrosine kinase inhibitor, Furmonertinib is centrally involved in ArriVent BioPharma's clinical trials, targeting multiple epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC). The drug is currently undergoing a phase 3 clinical trial specifically designed for patients with metastatic EGFRm NSCLC. Additionally, Furmonertinib is in a phase 1b clinical trial for the treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations. The development of Furmonertinib, with its focus on a key aspect of NSCLC, highlights the company's commitment to pioneering in the area of targeted cancer therapy.
ARR-002 represents another facet of ArriVent BioPharma's developmental pipeline, further emphasizing its dedication to expanding the range of treatment options available for cancer patients. While specific details on ARR-002 are more limited, its inclusion in the company's portfolio signifies its ongoing efforts in broadening its research and development activities to cover a wider spectrum of oncological needs.
The company has established strategic partnerships to enhance its product development capabilities and commercial outreach. Notably, ArriVent BioPharma collaborates with Aarvik Therapeutics Inc. for the discovery and development of antibody drug conjugates (ADCs) that aim for improved activity and safety over single target bivalent ADCs. Another significant partnership with Shanghai Allist Pharmaceuticals Co., Ltd. focuses on the development and commercialization of Furmonertinib. These alliances not only bolster the company’s operational strengths but also extend its impact on the global cancer treatment arena.